COVID-19
View plans for in-person Commencement and fall 2021 on our COVID-19 News & Information website.
Coronavirus/COVID-19 Information

Vaccines Required for University Housing Residents, Student-Athletes Participating in NCAA Athletics

Chico State will require COVID-19 vaccinations for students living in University Housing or participating in NCAA athletics, beginning in the fall 2021 semester.

---
Announced: April 15, 2021

In support of Chico State’s commitment to health and safety for all members of its community, the University will require COVID-19 vaccinations for students who are living in University Housing or participating in NCAA athletics, beginning in the fall 2021 semester. 

“Our plan is to open our residence halls at about 80 percent of full capacity, with two students in most rooms, in the fall. When athletics returns, our student-athletes will spend significant time together in shared facilities,” said Mike Guzzi, CSU, Chico’s emergency operations center director. “It’s critical that these two segments of the student population are vaccinated so we can safely plan for a full, lively Chico State in fall 2021.”

The University expects to house about 1,800 students for the 2021–22 academic year. Residence hall move-in dates are tentatively scheduled for August 16–20, 2021. University Housing will require students to have received their second (two-dose series vaccine) or first (for the single-dose vaccine) vaccination by July 30, 2021, in order to move into University Housing on their assigned move-in date. 

For the approximately 340 student-athletes currently participating in the University’s 13 NCAA intercollegiate sports, proof of vaccine will be required as part of their annual medical clearance process that begins in June. In order to gain medical clearance to participate in any sport for the 2021–22 academic year, a student-athlete must show proof of vaccination or complete the exemption validation process.

For both University Housing and Intercollegiate Athletics, any vaccine authorized for use in the United States (currently Moderna, Pfizer, and Johnson & Johnson) will be accepted.